↓ Skip to main content

Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions

Overview of attention for article published in Current Drug Metabolism, April 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#2 of 402)
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
4 news outlets

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions
Published in
Current Drug Metabolism, April 2017
DOI 10.2174/1389200218666170424151551
Pubmed ID
Authors

Peter Kubisz, Lucia Stanciakova, Miroslava Dobrotova, Matej Samos, Marian Mokan, Jan Stasko

Abstract

Apixaban is an oral, potent, highly selective, reversible and direct inhibitor of activated coagulation factor X, that is the end point of the intrinsic and extrinsic coagulation pathway. Additionally, apixaban has the capacity to indirectly inhibit thrombin-induced platelet aggregation. This new oral anticoagulant represents an immediate-release form of peroral drug with quick dissolution, linear pharmacokinetics, good bioavailability and rapid onset and offset of action. No clinically relevant age- or sex-dependent difference in the apixaban pharmacokinetics and pharmacodynamics which would lead to the modification of the dose exists, apixaban may even be administered with or without food. Its elimination is mediated by metabolism, renal elimination of unmodified drug and excretion in the gastrointestinal tract. The authors aim to provide a review of currently available literature about apixaban. The authors summed-up the data from the scientific journals related to thrombosis and hemostasis and searched the available databases. Apixaban has many advantages including predictable pharmacokinetics and pharmacodynamics, low number of drug and food interactions, and relatively wide therapeutic window.

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 5 38%
Researcher 3 23%
Other 2 15%
Student > Ph. D. Student 1 8%
Professor > Associate Professor 1 8%
Other 1 8%
Readers by discipline Count As %
Unspecified 6 46%
Medicine and Dentistry 5 38%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Design 1 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 October 2017.
All research outputs
#422,498
of 12,037,162 outputs
Outputs from Current Drug Metabolism
#2
of 402 outputs
Outputs of similar age
#20,172
of 285,123 outputs
Outputs of similar age from Current Drug Metabolism
#1
of 9 outputs
Altmetric has tracked 12,037,162 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 402 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,123 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them